PMID- 36250073
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221019
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 9
DP  - 2022
TI  - Immunological imprint on peripheral blood in kidney transplant recipients after 
      two doses of SARS-CoV-2 mRNA vaccination in Japan.
PG  - 999374
LID - 10.3389/fmed.2022.999374 [doi]
LID - 999374
AB  - The immunological imprint after two doses of severe acute respiratory 
      syndrome-coronavirus 2 (SARS-CoV-2) mRNA vaccination for patients after kidney 
      transplantation (KTx) remain unclear. This study included KTx recipients and 
      volunteer healthy controls (HCs) who received two doses of SARS-CoV-2 mRNA 
      vaccine (Pfizer BioNTech) from January 2021 to December 2021. We analyzed safety 
      within 21 days after each vaccination dose and compared the immune response in 
      peripheral blood mononuclear cells (PBMCs) between the two groups. No graft 
      rejection was observed throughout this study. Adverse events were generally 
      observed within 5 days. The KTx group exhibited a significantly lower degree of 
      symptoms between doses 1 and 2 (P < 0.001). Increases in activated subsets of T 
      and B cells expressing human leukocyte antigen (HLA)-DR and/or CD38 were observed 
      in the HC group after dose 2 (both P < 0.001), with the greatest increases in 
      HLA-DR(+)CD8(+) T cells and CD38(+)CD19(+) B cells (P = 0.042 and P = 0.031, 
      respectively). In addition, PD1(+)CD8(+) T cells-but not PD1(+)CD4(+) T 
      cells-increased significantly in the HC group (P = 0.027). In the KTx group, 
      however, activated HLA-DR(+), CD38(+), and PD1(+) cells remained at baseline 
      levels. Immunoglobulin (Ig)G against SARS-CoV-2 was detected in only four KTx 
      recipients (13.3%) after dose 2 (P < 0.001). Multivariate logistic regression 
      analyses revealed that DeltaHLA-DR(+)CD8(+) T cells and DeltaCD38(+)CD19(+) B cells were 
      significantly associated with IgG formation (both P = 0.02). SARS-CoV-2 mRNA 
      vaccine generates impaired cellular and humoral immunity for KTx recipients. 
      Results indicate the need for modified vaccination strategies in 
      immunocompromised KTx recipients.
CI  - Copyright (c) 2022 Takiguchi, Tomita, Uehara, Tateishi, Yamamoto and Nakamura.
FAU - Takiguchi, Shinya
AU  - Takiguchi S
AD  - Department of Transplant Surgery, Tokai University School of Medicine, Kanagawa, 
      Japan.
FAU - Tomita, Yusuke
AU  - Tomita Y
AD  - Department of Transplant Surgery, Tokai University School of Medicine, Kanagawa, 
      Japan.
FAU - Uehara, Saeko
AU  - Uehara S
AD  - Department of Transplant Surgery, Tokai University School of Medicine, Kanagawa, 
      Japan.
FAU - Tateishi, Koichiro
AU  - Tateishi K
AD  - Department of Virology, Division of Host Defense Mechanism, School of Medicine, 
      Tokai University, Kanagawa, Japan.
FAU - Yamamoto, Norio
AU  - Yamamoto N
AD  - Department of Virology, Division of Host Defense Mechanism, School of Medicine, 
      Tokai University, Kanagawa, Japan.
FAU - Nakamura, Michio
AU  - Nakamura M
AD  - Department of Transplant Surgery, Tokai University School of Medicine, Kanagawa, 
      Japan.
LA  - eng
PT  - Journal Article
DEP - 20220928
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC9553995
OTO - NOTNLM
OT  - SARS-CoV-2 mRNA vaccination
OT  - cellular and humoral immune responses
OT  - immunological imprint
OT  - kidney transplantation
OT  - safety
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/10/18 06:00
MHDA- 2022/10/18 06:01
PMCR- 2022/09/28
CRDT- 2022/10/17 05:34
PHST- 2022/07/21 00:00 [received]
PHST- 2022/09/12 00:00 [accepted]
PHST- 2022/10/17 05:34 [entrez]
PHST- 2022/10/18 06:00 [pubmed]
PHST- 2022/10/18 06:01 [medline]
PHST- 2022/09/28 00:00 [pmc-release]
AID - 10.3389/fmed.2022.999374 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2022 Sep 28;9:999374. doi: 10.3389/fmed.2022.999374. 
      eCollection 2022.